AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02296125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.
Study identification
- NCT ID
- NCT02296125
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 674 participants
Conditions and interventions
Conditions
Interventions
- AZD9291 80 mg/40 mg + placebo Drug
- Erlotinib 150/100 mg Drug
- Gefitinib 250 mg Drug
- Placebo AZD9291 80 mg/ 40 mg Drug
- Placebo Erlotinib 150/100mg Drug
- Placebo Gefitinib 250 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2, 2014
- Primary completion
- Jun 18, 2017
- Completion
- Nov 19, 2025
- Last update posted
- Apr 20, 2026
2014 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anaheim | California | 92801 | — |
| Research Site | Santa Rosa | California | 95403 | — |
| Research Site | West Hills | California | 91307 | — |
| Research Site | Tampa | Florida | 33612 | — |
| Research Site | Atlanta | Georgia | 30318 | — |
| Research Site | Atlanta | Georgia | 30322 | — |
| Research Site | Marietta | Georgia | 30060 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Bethesda | Maryland | 20817 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Minneapolis | Minnesota | 55407 | — |
| Research Site | Lebanon | New Hampshire | 03756 | — |
| Research Site | Salisbury | North Carolina | 28144 | — |
| Research Site | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 156 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02296125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02296125 live on ClinicalTrials.gov.